Company intelligence / Profile preview

Hebei Zeyun Biopharmaceutical Technology

Shijiazhuang, Hebei, China

Ownership: Private
Development stage: Other

Overview

Hebei Zeyun Biopharmaceutical Technology is a China-based pharmaceutical company focused on the development and commercialization of therapeutic products. Operating as a Marketing Authorization Holder (MAH), the company utilizes contract manufacturing organizations (CMOs) to produce its pharmaceutical products. Its lead commercial product is Palbociclib capsules (brand name Yiboxin), a CDK4/6 inhibitor approved in China for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The company maintains a commercial sales network within China to distribute its approved therapies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hebei Zeyun Biopharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hebei Zeyun Biopharmaceutical Technology.

Explore the full profile